Citizens Jmp Issues Positive Forecast for AxoGen (NASDAQ:AXGN) Stock Price

AxoGen (NASDAQ:AXGN) had its price objective lifted by Citizens Jmp from $34.00 to $42.00 in a report released on Tuesday,Benzinga reports. They currently have a market outperform rating on the medical equipment provider’s stock.

Several other research analysts have also recently commented on the company. Mizuho assumed coverage on AxoGen in a research report on Monday, December 1st. They set an “outperform” rating and a $40.00 price target for the company. Weiss Ratings reiterated a “sell (e+)” rating on shares of AxoGen in a research note on Monday, December 29th. Wall Street Zen raised shares of AxoGen from a “buy” rating to a “strong-buy” rating in a research note on Friday, January 23rd. Citigroup reaffirmed an “outperform” rating on shares of AxoGen in a research report on Tuesday. Finally, Canaccord Genuity Group increased their price target on shares of AxoGen from $27.00 to $37.00 and gave the company a “buy” rating in a research note on Friday, December 5th. Ten equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, AxoGen currently has an average rating of “Moderate Buy” and a consensus target price of $37.67.

AxoGen Stock Down 8.1%

AxoGen stock opened at $32.50 on Tuesday. The company has a current ratio of 4.09, a quick ratio of 2.64 and a debt-to-equity ratio of 0.54. AxoGen has a 1-year low of $9.22 and a 1-year high of $36.00. The company has a fifty day simple moving average of $33.09 and a 200 day simple moving average of $24.85. The company has a market cap of $1.50 billion, a P/E ratio of -650.00 and a beta of 1.00.

AxoGen (NASDAQ:AXGN) last posted its quarterly earnings data on Tuesday, February 24th. The medical equipment provider reported ($0.28) EPS for the quarter, missing analysts’ consensus estimates of $0.08 by ($0.36). The business had revenue of $59.90 million for the quarter, compared to analyst estimates of $59.90 million. AxoGen had a negative return on equity of 1.90% and a negative net margin of 0.98%. Research analysts anticipate that AxoGen will post -0.29 earnings per share for the current fiscal year.

Insider Buying and Selling at AxoGen

In other AxoGen news, Director Amy Mcbride Wendell sold 43,684 shares of the firm’s stock in a transaction that occurred on Tuesday, December 16th. The shares were sold at an average price of $29.31, for a total transaction of $1,280,378.04. Following the completion of the sale, the director directly owned 93,826 shares in the company, valued at $2,750,040.06. This trade represents a 31.77% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director John Johnson sold 21,686 shares of the business’s stock in a transaction that occurred on Tuesday, December 9th. The stock was sold at an average price of $29.98, for a total value of $650,146.28. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 301,680 shares of company stock worth $9,174,052 in the last ninety days. Insiders own 2.78% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. First Light Asset Management LLC grew its stake in AxoGen by 28.2% during the third quarter. First Light Asset Management LLC now owns 5,805,730 shares of the medical equipment provider’s stock worth $103,574,000 after buying an additional 1,276,487 shares in the last quarter. Vanguard Group Inc. lifted its holdings in shares of AxoGen by 7.1% during the 4th quarter. Vanguard Group Inc. now owns 2,869,955 shares of the medical equipment provider’s stock worth $93,934,000 after acquiring an additional 190,557 shares during the period. Morgan Stanley boosted its position in shares of AxoGen by 6.5% during the 4th quarter. Morgan Stanley now owns 2,586,870 shares of the medical equipment provider’s stock worth $84,668,000 after acquiring an additional 157,029 shares in the last quarter. ArrowMark Colorado Holdings LLC increased its stake in AxoGen by 20.4% in the third quarter. ArrowMark Colorado Holdings LLC now owns 1,958,406 shares of the medical equipment provider’s stock valued at $34,938,000 after acquiring an additional 332,498 shares during the last quarter. Finally, Balyasny Asset Management L.P. increased its stake in AxoGen by 183.9% in the second quarter. Balyasny Asset Management L.P. now owns 1,931,158 shares of the medical equipment provider’s stock valued at $20,953,000 after acquiring an additional 1,250,968 shares during the last quarter. 80.29% of the stock is owned by institutional investors and hedge funds.

Key AxoGen News

Here are the key news stories impacting AxoGen this week:

• Positive Sentiment: Company raised FY‑2026 revenue guidance to about $265.7M versus Street revenue near $258.5M, signaling stronger top‑line growth ahead; management also outlined strategy on the earnings call. MarketBeat Earnings Report
• Positive Sentiment: Analyst upgrade/target change: Citizens JMP raised its price target from $34 to $42 and kept a “market outperform” view, which could support upside if sentiment improves. Benzinga Note
• Positive Sentiment: Earnings‑call commentary and press materials emphasized continued revenue growth and strategic initiatives (commercial execution, product adoption), which underpins the raised guidance. Yahoo Finance Highlights
• Neutral Sentiment: Full earnings‑call transcripts and slide deck are available for investors to parse details on margin drivers and cadence; these materials may clarify timing of margin improvement. Seeking Alpha Transcript
• Negative Sentiment: Reported EPS of $0.07 missed some consensus figures (MarketBeat/Street ~$0.08; Zacks noted a larger gap vs its $0.14 estimate), which disappointed some investors and can pressure near‑term sentiment. Zacks Earnings Miss
• Negative Sentiment: Profitability remains weak: reported negative net margin (~‑0.98%) and negative ROE (~‑1.9%), keeping the stock’s valuation and path to sustained profitability under scrutiny. MarketBeat Metrics

AxoGen Company Profile

AxoGen, Inc is a Florida-based medical technology company that develops and commercializes surgical solutions for peripheral nerve damage. Founded in 2002 and headquartered in Alachua, Florida, the company focuses on restoring nerve function and improving patient outcomes through innovative biologic and engineered products. AxoGen’s offerings address a range of traumatic and iatrogenic injuries, offering alternatives to traditional nerve autografts.

The company’s core product portfolio includes the Avance® Nerve Graft, a decellularized human nerve allograft designed to bridge nerve gaps without the need for a secondary harvest site, and the Axoguard® Nerve Connector and Protector devices, which facilitate nerve coaptation and protect repaired sites from surrounding scar tissue.